三絲，ARDX如何

Ardelyx resubmitted its FDA market application for Xphozah in April, with a decision expected by Oct. 17. If approved, the company said it expects to be able to launch the drug in Q4. 

Cantor raised its price target for the stock to $10 from $5.

所有跟帖： 

• Ardx 目前不錯，在10月份FDA批準之前會漲一波，我前幾天買@4.25 -三絲- ♂ (0 bytes) () 09/01/2023 postreply 12:27:14